Gastrointestinal Cancer

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.

Randall F. Holcombe, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the oral multikinase inhibitor regorafenib for patients with metastatic colorectal cancer.

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Computer-aided computed tomographic colonography that does not require a laxative preparation nearly rivals conventional optical colonoscopy for identifying asymptomatic adults with adenomas.

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Patients 75 years of age or older with stage III colon cancer may expect a survival benefit from adjuvant chemotherapy that rivals that previously reported in younger patients.

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.

Two analyses, two different conclusions in Asian START trial when docetaxel was added to S-1 for patients with previously untreated advanced or recurrent gastric cancer.

Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

A secondary analysis of a combination of an investigational hypoxia-targeted agent called TH-302 with gemcitabine slightly improved overall survival, but the results were not statistically significant.

The Trials in Progress Poster Session at the ASCO Annual Meeting, now in its third year, is intended to stimulate discussion in the oncology community about ongoing clinical trials and to promote collaboration.

Colonoscopy is effective for the prevention of colorectal cancer deaths, according to the results of a large, population-based, case-control study.

Tivantinib has demonstrated statistically significant improvements in time to progression and overall survival versus placebo among patients with unresectable hepatocellular carcinoma.

The oral multikinase inhibitor regorafenib extended OS in patients with metastatic colorectal cancer and improved PFS in patients with gastrointestinal stromal tumors.

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.

The phase III VELOUR trial demonstrated that the addition of aflibercept to FOLFIRI improved overall survival compared with placebo plus FOLFIRI in patients with metastatic colorectal cancer.

Dr. RuiRong Yuan, from Daiichi Sankyo, on the Efficacy of Tivantinib for Patietns With Hepatocellular Carcinoma.

Colon cancer is equally as likely as breast and ovarian cancer to be hereditary (approximately 10% of cases, overall) and there are many different genes responsible for these cases.

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

Three-fourths of patients with advanced hepatocellular carcinoma associated with hepatitis C infection achieved disease control with antibody therapy directed at a T-cell antigen.

The phase III EXPAND trial of cetuximab in combination with standard chemotherapy for patients with advanced gastric adenocarcinoma failed to show a significant improvement in progression-free survival.

Four studies reflected the growing interest in-and the volume of evidence for-using the diabetes drug metformin as a potential cancer therapy.

Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer